The invasive effects of MMP13 on cancer cells can be mediated through six novel targets, including the inactivation of chemokine C-C motif ligand 2 (CCL2) and CCL7, activation of platelet-derived growth factor-C (PDGF-C) and cleavage of SAA3, osteoprotegerin (OPG), CutA and antithrombin III [108]. Here, CCL2 is linked to cancer.